The litigation centers on allegations that Grail misled shareholders regarding the efficacy of its NHS-Galleri cancer detection trial. Throughout the class period, the company consistently touted the trial's design and its ability to achieve a statistically significant reduction in Stage III and IV cancers. However, on February 19, 2026, Grail disclosed that the study failed to meet its primary endpoint, citing an insufficient follow-up period. This announcement caused the company's stock price to plummet from $101.53 to $50.21 per share in a single day, representing a loss of approximately 50.55%.
Grail Investors Face August Deadline in Securities Class Action
Investors who purchased Grail, Inc. stock between May 13, 2025, and February 19, 2026, have until August 4, 2026, to seek lead plaintiff status in a federal securities class action. The lawsuit follows a sharp stock decline triggered by the company’s failure to meet primary clinical trial endpoints.
Faruqi & Faruqi, LLP is currently investigating these claims and encouraging affected shareholders to evaluate their legal options. While the court will appoint a lead plaintiff based on the largest financial interest in the case, individual investors are not required to take active roles to remain part of the class. Those seeking to participate as lead plaintiff must file their motion by the August 4, 2026, deadline. The firm is also soliciting information from former employees and whistleblowers who may have insight into the company’s internal handling of the NHS-Galleri trial data.
Comments (0)
No comments yet. Be the first!